JNJ Research Archive

Johnson & Johnson (JNJ) is trading marginally higher by 0.15%, largely moving in sympathy with the wider market. While it continues to trade well above its 200-day moving average of $211.15, the lack of idiosyncratic catalysts leaves the stock currently dependent on macro-level flows to dictate its direction for the day.

JNJ is showing defensive characteristics, trading up 0.15% even as the SPY faces a broad-based sell-off. The stock is currently trading well above its 200-day SMA of $211.15, underscoring a solid long-term trend. In the absence of company news, the stock's ability to maintain a positive print highlights its role as a non-correlated asset during today's market drawdown.

Johnson & Johnson (JNJ) is posting a modest gain of 0.27% in early trade. The stock remains in a strong technical position, holding well above its 200-day moving average of $211.15. Absent specific company news, the stock is tracking the broader market trend, though it is currently trailing the aggressive gains seen in the wider S&P 500.

Johnson & Johnson (JNJ) is essentially flat with a gain of 0.08%, showing extreme relative weakness compared to the 2.12% surge in the SPY. With no primary or sector-specific news, the stock is failing to participate in the general market optimism. It remains safely above its 200-day moving average of $211.15, but momentum remains suppressed as investors shift capital into higher-beta areas of the market.

Johnson & Johnson shares are trading 0.83% higher following the announcement that Royalty Pharma will commit $500M toward the development of J&J's autoimmune drug portfolio. This capital influx is providing a fresh catalyst for the stock, allowing it to show relative strength against the wider market.

Shares of Johnson & Johnson (JNJ) are trading lower by 4.66%, failing to gain traction despite the positive news regarding Royalty Pharma's $500M commitment to its autoimmune drug pipeline. The stock is clearly being dragged down by the massive liquidity drain in the broader market today. While JNJ is holding above its 200-day moving average ($211.15), the company-specific news is being entirely overshadowed by the aggressive macro-driven selloff.

Shares of Johnson & Johnson (JNJ) are trading higher by 0.57%, showcasing defensive strength as the wider market succumbs to a morning sell-off. Absent any specific news, the move suggests a rotation into healthcare staples. JNJ continues to maintain its position well above its 200-day SMA of $208.42. While the MACD is still attempting to recover, the stock’s ability to defend price levels during a down day for the SPY suggests a tactical rotation favoring the sector.

Shares of Johnson & Johnson (JNJ) are posting a significant 4.86% decline today. While the lack of company-specific headlines suggests this is not earnings-related, the intensity of the selling—dropping the stock toward its 200-day moving average of $208.42—indicates a major shift in investor positioning. Investors should monitor whether the $220 level can serve as a floor to prevent a deeper technical breakdown.

JNJ is slightly higher by 0.2% this morning, demonstrating defensive relative strength while the SPY remains slightly in the red. In the absence of company-specific news, the stock is benefiting from its position as a rotation target for investors seeking stability during periods of macro-uncertainty. The stock is trading well above its 200-day moving average of $208.42, maintaining a constructive technical posture.

Johnson & Johnson (JNJ) is standing as an outlier today, posting a modest 0.4% gain despite a -0.99% drop in the SPY. While no company news exists, the stock is benefiting from its status as a defensive healthcare play amid broader market volatility. It continues to hold well above its 200-day SMA of $208.42, signaling relative strength in a risk-off environment.

Johnson & Johnson (JNJ) is trading up 1.59% despite negative pressure on the S&P 500. With no direct news catalysts, the move appears to be a technical rotation into defensive healthcare assets. The stock remains firmly above its 200-day SMA, indicating a stable long-term uptrend despite recent MACD volatility.

With no specific catalysts or sector news to report, Johnson & Johnson (JNJ) is tracking the broader market lower, down 3.05%. The stock is showing neutral relative strength, simply participating in the overarching macro-driven selloff. While still trading above its 200-day SMA ($208.42), the trend is softening as it moves lower.

Johnson & Johnson (JNJ) is underperforming, down 3.0% in early action. With no direct catalysts, the drop reflects a lack of buyer interest in the healthcare sector. The stock is currently testing levels well below its 200-day moving average, and failing to defend the $220 support zone could accelerate the current downtrend.

Johnson & Johnson (JNJ) is trading slightly lower by 0.27%, largely mirroring the lack of movement in the broader healthcare sector and the flat S&P 500. The stock is currently showing neither strength nor weakness relative to the market. Crucially, JNJ remains well-supported above its 200-day moving average of $208.42, keeping its long-term technical structure stable despite the lack of catalysts.

JNJ shares are up 0.78%, trending with the overall market recovery. While the stock remains under a technical bearish divergence based on its MACD positioning, the current move is largely tied to macro sentiment. Defensive investors should watch for a firm consolidation above the $230 level to confirm a shift in near-term momentum.

JNJ shares are showing relative weakness, trading down 1.77% while the S&P 500 records strong gains. Typical of defensive names, the stock is seeing capital rotation away from the healthcare sector as investors chase higher-beta assets in the current market surge. The stock continues to hold above its 200-day moving average of $208.08, which remains the key line in the sand for long-term holders.

Johnson & Johnson (JNJ) is trading down 0.55% as part of a general pullback in the Healthcare sector, which is down 1.60%. The stock continues to hold well above its 200-day moving average of $206.71, indicating a healthier structural setup compared to the broader market index. JNJ remains a defensive play today, showing less volatility than the broader indices.

Johnson & Johnson (JNJ) is trading down 2.25%, mirroring the broader weakness in the Healthcare sector, which is retreating by roughly 3%. Despite a lack of direct news, the stock is being dragged down by the wider sector sell-off. Currently trading well above its 200-day moving average, JNJ remains in a relatively stable technical position compared to the broader market index.

Johnson & Johnson (JNJ) is trading higher by 0.2% following the FDA approval of its new psoriasis pill. The news has drawn positive reiterations from both Guggenheim and BofA analysts, providing a tailwind for the stock despite general weakness in the Healthcare sector. JNJ is displaying clear relative strength today and continues to hold comfortably above its 200-day moving average.

Johnson & Johnson (JNJ) is trading essentially flat (+0.02%) on the day, effectively outperforming the struggling Healthcare sector. The stability comes following a reiteration of the stock's rating by Guggenheim, linked to recent FDA approval news. With the stock holding steady above its 200-day SMA of $206.71, it remains a defensive bright spot during today's sector-wide weakness.

Johnson & Johnson (JNJ) is trading down 2.87%, showing relative weakness compared to the broader market. While the stock received a positive boost from the FDA approval of its oral psoriasis pill, the news is being overshadowed by broader legal headwinds regarding drugmaker overcharge claims. JNJ is currently struggling to maintain momentum, and the technical setup remains pressured as it reacts to the net-negative impact of the litigation headlines.

Johnson & Johnson (JNJ) is proving its mettle today, trading flat despite a 4% drop in the broader Healthcare sector. The stock is bolstered by positive sentiment surrounding the FDA approval of its new oral psoriasis pill. With multiple analyst notes echoing the potential for market share gains, JNJ is displaying clear relative strength against its sector peers.

Johnson & Johnson (JNJ) is bucking the trend, posting a 0.3% gain while the broader Healthcare sector and the S&P 500 drift lower. In the absence of company-specific headlines, this performance highlights defensive rotation. The stock is attempting to move higher after a constructive technical setup, currently trading well above its 200-day moving average.

Johnson & Johnson (JNJ) shares are down 6.92% following reports that major drugmakers must face federal claims regarding overcharging for medications. The decline is outpacing the broader healthcare sector, highlighting investor concern over legal liabilities. The stock remains above its 200-day moving average, but investors are clearly pricing in the heightened regulatory scrutiny.

Johnson & Johnson (JNJ) is edging up 0.43%, contrasting with a 1.53% decline in the broader Healthcare sector. The stock remains in a strong technical uptrend, currently trading comfortably above its 200-day moving average of $205.62, signaling institutional support despite sector-wide weakness.

JNJ is under significant pressure, dropping 4.98% mid-day. While the healthcare sector is down 1.30%, JNJ is showing distinct relative weakness, accelerating the downward trend. The stock is currently testing the $229 support level; a failure to hold here would signal a significant technical break given the stock is still trading above its 200-day SMA.

Johnson & Johnson (JNJ) is showing relative strength this morning, gaining 0.65% against a struggling Healthcare sector that is down 2.55%. In the absence of company-specific headlines, the price action is likely a defensive play by investors. The stock continues to trade significantly above its 200-day SMA, indicating a sustained positive trend.

Despite some positive sentiment regarding dividend-yielding assets in periods of market panic, JNJ is trading down 4.9%. The stock is facing significant headwinds as it sheds value alongside a broader -2.66% decline in the healthcare sector. Investors are currently prioritizing liquidity over defensive yield plays.

Johnson & Johnson (JNJ) is trading down 0.43%, tracking the broader Healthcare sector's decline of over 2%. Despite the lack of specific news, JNJ is currently yielding to general market volatility. Technically, the stock remains in a relatively constructive position compared to its 200-day SMA, but investors should watch for a defense of recent lows to maintain its current bullish technical trend.

Johnson & Johnson (JNJ) is trading down 0.43%, showing notable resilience compared to the wider Healthcare sector, which is nursing losses of over 3.6%. While technicals suggest a mild cooling, JNJ’s ability to outperform its sector peers during this broad market consolidation highlights relative defensive strength.

Johnson & Johnson (JNJ) shows no change in pre-market trading, failing to react to broader market conditions. The stock is currently navigating a tough environment, as the Healthcare sector is seeing a marked 12.6% decline. Despite this, JNJ maintains a constructive position above its 200-day moving average of $203.15, suggesting some relative resilience despite the sectoral headwinds.

Johnson & Johnson (JNJ) is trading down 0.11%, demonstrating relative strength compared to the Healthcare sector, which is down 1.87%. There is no company-specific news to drive the price action; the stock is trading within its recent range and remains well supported by its technical trend, trading significantly above the $203.16 200-day moving average. Investors are keeping a close watch on the $240 level as a test of support.

Johnson & Johnson (JNJ) faced heavy selling pressure, dropping 5.29% to close at $230.12. While no company-specific news was reported, the decline was exacerbated by a general rot in the Healthcare sector, which slid nearly 2%. The stock is now testing lower bounds; investors should watch to see if it can maintain distance from the $203.58 200-day SMA.

Johnson & Johnson (JNJ) enters the morning session flat, feeling the weight of a 7.8% pullback in the broader healthcare sector. While the stock remains comfortably above its 200-day SMA, the weakening sector trend and a waning MACD momentum suggest a cautious tone for the session ahead.

JNJ is showing resilience, trading up 0.41% while the Healthcare sector faces a drag of 1.35%. With no direct catalysts, the stock is demonstrating relative strength, acting as a defensive anchor for portfolios. The stock continues to trade well above its 200-day SMA, indicating a stable long-term trend despite broader volatility in healthcare names.

JNJ posted a modest 0.47% gain, demonstrating significant relative strength as the Healthcare sector dropped over 2.6%. Despite the broader sector retreat, JNJ managed to hold its ground, closing at $242.67. Investors will look to see if this outperformance can be sustained, though the stock remains well above its 200-day moving average, providing a solid cushion for shareholders.

Johnson & Johnson is showing a lack of momentum this morning, constrained by a broad 7.9% downturn in the Healthcare sector. Despite trading well above its 200-day SMA, the recent MACD divergence suggests that the bullish trend is losing conviction. Without company-specific news, JNJ remains vulnerable to the broader defensive sector rotation.

JNJ is posting a solid 2.84% gain, significantly outperforming the Healthcare sector which is down 1.07%. With no headline catalysts, this upward move represents a strong technical recovery. The stock remains comfortably above its 200-day moving average ($201.42), suggesting buyers are stepping in to defend current price levels.

Johnson & Johnson (JNJ) managed a 0.54% gain during a session that saw the Healthcare sector slide 1.34%. Trading in a calm range, JNJ continues to act as a defensive anchor for portfolios. The stock is holding comfortably above its 200-day moving average, signaling a constructive technical setup despite the lack of direct news catalysts.

Johnson & Johnson (JNJ) is starting the day under pressure, reflecting a wider sell-off in the healthcare sector. Despite the absence of specific company news, the stock's recent weakness mirrors the broader contraction within its peer group. While JNJ is holding above its 200-day SMA of $200.57, the negative MACD momentum and recent technical drift suggest buyers are currently sidelined.

Johnson & Johnson (JNJ) is trading lower by 3.67%, showing slight relative weakness against the broader Healthcare sector's 2.45% decline. In the absence of company-specific developments, the downward pressure is largely macro-driven, tracking the general market malaise. The stock remains well above its 200-day SMA, though the current velocity of the move is concerning for near-term bulls.

Johnson & Johnson (JNJ) posted a modest gain of 0.35%, effectively decoupling from a weak Healthcare sector that finished deep in the red. The stock continues to show defensive characteristics, holding well above its 200-day moving average of $200.99, indicating a rotation into safety as investors navigate broader market volatility.

Shares of Johnson & Johnson (JNJ) are showing relative strength in pre-market trading, up 0.82% to $245.26. This move comes as the healthcare giant announced the launch of a new website for direct-to-consumer sales, a strategic pivot signaling a more direct engagement with its customer base. JNJ's gains are outpacing the broader S&P 500, which is currently up 0.5%, and also outperforming the Healthcare sector's 0.46% rise. This positive reaction suggests investors are optimistic about the potential for increased market penetration and revenue streams from the new direct sales channel as the market prepares to open.

Shares of Johnson & Johnson (JNJ) are facing significant selling pressure mid-day, trading down 4.98% at $231.15. This marks a notable underperformance against the broader market, which is only slightly negative (SPY -0.17%), indicating strong relative weakness for JNJ today. The decline comes despite news that the company has launched a new website for direct-to-consumer sales, a move typically viewed as positive for brand engagement and margins. However, the market appears to be reacting negatively or with skepticism to the news, failing to lift the stock. Adding to the headwinds, the broader Healthcare sector is also struggling, down 2.77% today, exacerbating J&J's decline. The stock has broken below its opening levels and is trending lower, testing new intraday lows.

Shares of Johnson & Johnson (JNJ) closed out the session significantly lower, down 1.79% at $238.91. This decline occurred despite the company's announcement of a new direct-to-consumer sales website, a development that typically would be viewed as positive. The stock's performance largely tracked, and slightly underperformed, a broader sell-off in the Healthcare sector, which finished down 1.69% for the day. Adding to the relative weakness, JNJ was unable to participate in the broader market, which saw the S&P 500 dip only modestly by 0.27%. The stock opened at its day's low of $243.26 (which also served as yesterday's close) before attempting a rally to $246.78, ultimately rolling over to close near its session lows, indicating strong selling pressure.

Shares of Johnson & Johnson (JNJ) are poised for a strong open, currently trading higher by 1.43% in the pre-market session. This performance signifies notable relative strength, as JNJ is comfortably outperforming both its Healthcare sector (+1.06%) and the broader S&P 500 (+0.78%). With no company-specific or sector-specific high-impact news reported, the move appears to be driven by robust buying interest and positive technical momentum, especially given the stock's significant gap up from its indicated prior close. JNJ looks set to open above key levels, demonstrating conviction from buyers.

Shares of Johnson & Johnson (JNJ) are posting solid gains mid-day, trading up 1.05% at $245.81. The stock is showing relative strength against the broader market, outperforming the S&P 500's 0.65% climb. While there's no specific company news, JNJ is benefiting from a strong uplift across the Healthcare sector, which is currently leading with a 2.18% advance. JNJ is participating in this sector-wide momentum, trading near its day's high of $246.78, although it is slightly underperforming its sector peers today.

Shares of Johnson & Johnson (JNJ) closed the session significantly lower, finishing down 1.79% at $238.91 in post-market trading. This represents a notable underperformance, as the broader Healthcare sector rallied 1.52% and the S&P 500 closed up 0.56%. With no company-specific news or high-impact sector news to explain the move, JNJ's decline appears technically driven, possibly reflecting profit-taking or a failure to hold key levels. The stock traded between a day high of $246.78 and a low of $243.26 before drifting lower into the close, showing considerable relative weakness against the market.

Shares of Johnson & Johnson (JNJ) are showing robust performance in pre-market trading, gapping up 2.14% to trade at $248.47. This strong move higher significantly outpaces both the broader Healthcare sector, which is up 0.63%, and the S&P 500, which is currently in the red, down 0.21%. With no specific company or sector news driving the move, the strong buying interest appears to be technically driven, positioning JNJ for a notable open. The stock is demonstrating clear relative strength ahead of the bell.

Johnson & Johnson (JNJ) is trading in the red during midday action, with shares down 1.82% at $238.83. This move stands in stark contrast to the broader market and sector, as the S&P 500 is up 0.32% and the Healthcare sector is showing slight gains of 0.135%. With no high-impact company-specific or sector news to drive the move, JNJ is exhibiting significant relative weakness, suggesting profit-taking or technical selling pressure. The stock opened at $243.26 and has steadily trended lower, now testing levels well below its initial intraday low. Traders will be watching to see if JNJ can find support to prevent further downside momentum into the close.

Shares of Johnson & Johnson (JNJ) closed out the session with significant upside momentum, ending the day up a robust 3.97% at $252.92. This impressive performance vastly outstripped the broader market, which saw the S&P 500 gain 0.76%, and also eclipsed the healthcare sector's more modest 1.05% advance. With no specific company or sector news to drive the move, the buying interest appears to be purely technical, highlighted by the stock's closing price significantly above its intraday high of $246.78. This strong close suggests a breakout from recent trading ranges and solid underlying demand.